Overview
Ncardia specializes in iPSC technology, offering high-quality stem cell derivation, differentiation, and manufacturing for cardiac and neuronal applications in drug discovery. They provide custom disease models, assay development, and screening services using human iPSC-derived cells to enhance efficacy and safety assessments across small molecules, biologics, cell, gene, and RNA therapies. Their solutions support early-stage pipelines with scalable, automated assays that improve translational relevance over animal models.
Frequently asked questions
- What iPSC services does Ncardia offer for pharma R&D?
- Ncardia provides iPSC generation, at-scale differentiation, cell manufacturing, disease modeling, assay development, and custom screening for cardiac and neuronal applications in drug discovery pipelines.
- What therapeutic modalities do Ncardia's assays support?
- Assays support small molecules, biologics, cell, gene, and RNA therapies, delivering clinically relevant data on efficacy and safety using human iPSC-derived models.
- What assay capabilities does Ncardia have for cardiac safety?
- Capabilities include multielectrode array (MEA) analysis for electrophysiological profiling in iPSC-derived cardiomyocytes, plus automated cardiac microtissue platforms for high-throughput screening.